NDA 022257 · Cheplapharm
Valcyte
Valganciclovir Hydrochloride · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Dec 23, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Aug 28, 2009
Approved uses
3
Original approval plus efficacy supplements
Registered trials
120
36 Phase 3, 19 recruiting
FAERS reports
19,081
17,710 serious, 3,264 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS Hematologic Toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure including aplastic anemia have been reported in patients treated with VALCYTE [see Warnings and Precautions (5.1) ]. Impairment of Fertility: Based on animal data and limited human data, VALCYTE may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females [see Warnings and Precautions (5.3) ]. Fetal Toxicity: Based on animal data, VALCYTE has the potential to cause birth defects in humans [see Warnings and Precautions (5.4) ]. Mutagenesis and Carcinogenesis: Based on animal data, VALCYTE has the potential to cause cancers in humans [see Warnings and Precautions (5.5) ]. WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF...
What it is approved for
From the label in effect Dec 8, 2025.
VALCYTE is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients ( 1.2 ) Prevention of CMV disease in kidney and heart transplant patients at high risk. 1.1 Adult Patients Treatment of Cytomegalovirus (CMV) Retinitis: VALCYTE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) [see Clinical Studies (14.1) ] . Prevention of CMV Disease: VALCYTE is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]) [see Clinical Studies (14.1) ] . 1.2 Pediatric Patients Prevention of CMV Disease: VALCYTE is indicated for the prevention of CMV disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see Clinical Studies (14.2) ] .
Mechanism: Valganciclovir is an antiviral drug with activity against CMV [see Microbiology (12.4) ] . Mechanism of Action: Valganciclovir is an L-valyl ester (prodrug) of ganciclovir that exists as a mixture of two diastereomers. After oral administration, both diastereomers are rapidly converted to ganciclovir by intestinal and hepatic esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, which inhibits replication of human CMV in cell culture and in vivo. In CMV-infected cells, ganciclovir is initially phosphorylated to ganciclovir monophosphate by the viral protein kinase, pUL97....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 2, 2018 Supplement 9 · Efficacy LetterLabel
- Apr 23, 2015 Supplement 5 · Efficacy LabelLetter
- Aug 28, 2009 Original approval · Type 3 - New Dosage Form · priority review ReviewPediatric Medical ReviewPediatric Clinical Pharmacology Review
1 products under this application
- VALCYTE · VALGANCICLOVIR HYDROCHLORIDE 50MG/ML · FOR SOLUTION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Valganciclovir" as an intervention, any sponsor and status, largest first.
- Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03443869 · 601 participants · Start May 3, 2018 · Primary completion Apr 5, 2022
Drug: Letermovir; Valganciclovir and 4 more · For: CMV Disease
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 94 sites in all
- Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe PneumoniaPivotal-lookingCompleted
Hospital Universitario 12 de OctubreAcademic, hospital or other
NCT03915366 · 563 participants · Start Mar 1, 2020 · Primary completion Jan 31, 2025
Drug: Valganciclovir Oral Solution [Valcyte]; Tuberculostatic Agents · For: Pneumonia; HIV/AIDS; Tuberculosis and 1 more
Sites: Abidjan, Côte d’Ivoire; Bourdeaux, France; Toulouse, France · 13 sites in all
- A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell TransplantsPivotal-lookingCompleted
ShireTakeda (TAK)
NCT02927067 · 553 participants · Start Apr 14, 2017 · Primary completion Jul 1, 2022
Drug: Maribavir; Valganciclovir · For: Cytomegalovirus (CMV)
Sites: Birmingham, Alabama; Los Angeles, California; Stanford, California · 129 sites in all
- Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by InjectionPivotal-lookingStatus unknown
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00017784 · 500 participants
Drug: Valganciclovir · For: Cytomegalovirus Retinitis; HIV Infections
Sites: Beverly Hills, California; Paramount, California; San Francisco, California · 9 sites in all
- Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R RecipientsPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06798909 · 360 participants (planned) · Start Jul 22, 2025 · Primary completion Nov 30, 2030
Drug: Valganciclovir (Pre-emptive CMV Therapy); Valganciclovir CMV Prophylaxis · For: Cytomegalovirus (CMV); Kidney Transplant; Complications; Kidney Diseases
Sites: San Francisco, California; Miami, Florida; Atlanta, Georgia · 8 sites in all
ShireTakeda (TAK)
NCT02931539 · 352 participants · Start Dec 22, 2016 · Primary completion Aug 17, 2020
Drug: Maribavir; Ganciclovir and 3 more · For: Cytomegalovirus (CMV)
Sites: Birmingham, Alabama; Tucson, Arizona; Duarte, California · 134 sites in all
- Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIVPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00006145 · 350 participants · Start Aug 2000
Drug: Valganciclovir · For: Cytomegalovirus Infections; HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 57 sites in all
- IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft RecipientsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00294515 · 326 participants · Start Mar 31, 2006 · Primary completion Aug 31, 2008
Drug: Valganciclovir; Valganciclovir · For: Cytomegalovirus Infections
Sites: Birmingham, Alabama; Los Angeles, California; San Diego, California · 80 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use3,071
- cytomegalovirus infection1,840
- drug ineffective1,540
- neutropenia1,189
- pyrexia967
- leukopenia960
- diarrhoea952
- acute kidney injury862
- cytomegalovirus viraemia770
- death762
- pancytopenia717
- drug resistance683
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 83 |
| 2005 | 143 |
| 2006 | 102 |
| 2007 | 115 |
| 2008 | 144 |
| 2009 | 159 |
| 2010 | 175 |
| 2011 | 409 |
| 2012 | 518 |
| 2013 | 413 |
| 2014 | 513 |
| 2015 | 555 |
| 2016 | 608 |
| 2017 | 1,078 |
| 2018 | 1,375 |
| 2019 | 1,683 |
| 2020 | 1,823 |
| 2021 | 1,563 |
| 2022 | 1,563 |
| 2023 | 1,673 |
| 2024 | 1,891 |
| 2025 | 1,509 |
| 2026 | 986 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Valcyte (Valganciclovir HCl)
2024 spending
$85K
Beneficiaries
n/a
12 claims
Per beneficiary
n/a
$73.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $85,323 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Avery RK, Alain S, Alexander BD, et al. · Clin Infect Dis 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Valganciclovir for symptomatic congenital cytomegalovirus disease.
Kimberlin DW, Jester PM, Sánchez PJ, et al. · N Engl J Med 2015 · Comparative Study, Multicenter Study
- A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
Reischig T, Vlas T, Kacer M, et al. · J Am Soc Nephrol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
Papanicolaou GA, Avery RK, Cordonnier C, et al. · Clin Infect Dis 2024 · Clinical Trial, Phase III, Multicenter Study
- Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N, Winston DJ, Razonable RR, et al. · JAMA 2020 · Comparative Study, Multicenter Study
- Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.
Asberg A, Humar A, Rollag H, et al. · Am J Transplant 2007 · Multicenter Study, Randomized Controlled Trial
Sponsor: Cheplapharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.